Discovery of novel conjugates of quinoline and thiazolidinone urea as potential anti-colorectal cancer agent

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49.
   PubMed Web of Science ®Google Scholar
• Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet 2019;394:1467–80.
   PubMed Web of Science ®Google Scholar
• Parisi A, Porzio G, Pulcini F, et al. What is known about theragnostic strategies in colorectal cancer. Biomedicines 2021;9:140.
   PubMed Web of Science ®Google Scholar
• Venook A. Gastrointestinal cancer. Oncologist 2005;10:250–61.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adem R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27:1386–422.
   PubMed Web of Science ®Google Scholar
• Nalli M, Puxeddu M, La Regina G, et al. Emerging therapeutic agents for colorectal cancer. Molecules 2021;26:7463.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011;129:245–55.
   PubMed Web of Science ®Google Scholar
• García-Alfonso P, Martín AJM, Morán LO, et al. Oral drugs in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol 2021;13:17588359211009001–16.
   Web of Science ®Google Scholar
• Sun Q, Zhou J, Zhang Z, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther 2014;15:1635–45.
   PubMed Web of Science ®Google Scholar
• Deng Y, Li X. Fruquintinib and its use in the treatment of metastatic colorectal cancer. Futur Oncol 2019;15:2571–6.
   PubMed Web of Science ®Google Scholar
• Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225:1–26.
   PubMed Web of Science ®Google Scholar
• Faham N, Welm AL. RON signaling is a key mediator of tumor progression in many human cancers. Cold Spring Harb Symp Quant Biol 2016;81:177–88.
   PubMedGoogle Scholar
• Jung KH, Park BH, Hong SS. Progress in cancer therapy targeting c-met signaling pathway. Arch Pharm Res 2012;35:595–604.
   PubMed Web of Science ®Google Scholar
• Danilkovitch-Miagkova A. Oncogenic signaling pathways activated by RON receptor tyrosine kinase. Curr Cancer Drug Targets 2003;3:31–40.
   PubMed Web of Science ®Google Scholar
• Yin B, Liu Z, Wang Y, et al. RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells. Oncol Rep 2017;37:3209–18.
   PubMed Web of Science ®Google Scholar
• Wang MH, Wang D, Chen YQ. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis 2003;24:1291–300.
   PubMed Web of Science ®Google Scholar
• Wang J, Rajput A, Kan JL, et al. Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma. J Biol Chem 2009;284:10912–22.
   PubMed Web of Science ®Google Scholar
• Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006;6:637–45.
   PubMed Web of Science ®Google Scholar
• Kim SA, Lee KH, Lee DH, et al. Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma. Int J Oncol 2019;55:513–26.
   PubMed Web of Science ®Google Scholar
• Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat Rev Cancer 2018;18:341–58.
   PubMed Web of Science ®Google Scholar
• Yao HP, Zhou YQ, Zhang R, et al. MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer 2013;13:466–81.
   PubMed Web of Science ®Google Scholar
• Zhou YQ, He C, Chen YQ, et al. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene 2003;22:186–97.
   PubMed Web of Science ®Google Scholar
• Dai Y, Siemann DW. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Canc Therapeut 2010;9:1554–61.
   PubMed Web of Science ®Google Scholar
• Northrup AB, Katcher MH, Altman MD, et al. Discovery of 1-[3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): a specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met. J Med Chem 2013;56:2294–310.
   PubMed Web of Science ®Google Scholar
• Parikh PK, Ghate MD. Recent advances in the discovery of small molecule c-Met Kinase inhibitors. Eur J Med Chem 2018;143:1103–38.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Xu X, Wang F, et al. Discovery of 4-((4-(4-(3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)ureido)-2-fluorophenoxy)-6-methoxyquinolin-7-yl)oxy)-N,N-diethylpiperidine-1-carboxamide as kinase inhibitor for the treatment of colorectal cancer. Bioorg Chem 2021;106:104511.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Xu X, Wang F, et al. Identification of novel quinoline analogues bearing thiazolidinones as potent kinase inhibitors for the treatment of colorectal cancer. Eur J Med Chem 2020;204:112643.
   PubMed Web of Science ®Google Scholar
• Shi L, Wu TT, Wang Z, et al. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors. Eur J Med Chem 2014;84:698–707.
   PubMed Web of Science ®Google Scholar
• Qi B, Yang Y, Gong G, et al. Discovery of N1-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment. Eur J Med Chem 2019;163:10–27.
   PubMed Web of Science ®Google Scholar